2018 年第 12 期 第 13 卷

利拉鲁肽与门冬胰岛素30注射液联合治疗2型糖尿病的效果评价

Effect of liraglutide combined with insulin aspart 30 injection on type 2 diabetes mellitus

作者：张伟何斐王文泮瑛瑛应巧

英文作者：

单位：318000浙江省台州市立医院内分泌科（张伟、何斐、泮瑛瑛、应巧）；310009杭州，浙江大学医学院附属第二医院内分泌科（王文）

英文单位：

关键词：2型糖尿病；利拉鲁肽；门冬胰岛素30注射液；认知功能障碍

英文关键词：

• 摘要：

• 【摘要】目的    探究利拉鲁肽联合门冬胰岛素30注射液治疗2型糖尿病的临床效果及对患者认知功能障碍的影响。方法    连续入选2014年9月至2016年1月于浙江省台州市立医院内分泌科住院治疗的2型糖尿病患者132例，通过随机数字表法将患者分为对照组和观察组，每组66例。对照组采用门冬胰岛素30注射液治疗；观察组采用利拉鲁肽联合门冬胰岛素30注射液皮下注射治疗。治疗前及治疗12个月后比较2组患者的血糖、血脂、体重指数以及认知功能量表［包括简易智力状态检查量表（MMSE）、蒙特利尔认知评估量表（MoCA）和临床记忆量表（CMS）］评分。结果    治疗12个月后，2组血糖、血脂指标及体重指数均较治疗前明显下降；观察组空腹血糖、糖化血红蛋白和体重指数明显低于对照组［（6.0±1.4）mmol/L比（6.9±1.1）mmol/L、（6.0±1.8）%比（7.6±1.6）%、（25.9±6.8）kg/m2比（27.9±5.4）kg/m2］，差异均有统计学意义（均P＜0.05）。治疗12个月后，2组MMSE、MoCA和CMS总分均较治疗前明显增高；观察组的MMSE、MoCA和CMS总分明显高于对照组［（26.9±3.5）分比（25.0±2.8）分、（27.1±4.4）分比（25.3±3.3）分、（81±12）分比（74±10）分］，差异均有统计学意义（均P＜0.05）。结论    利拉鲁肽联合门冬胰岛素30注射液在控制血糖、降血脂、改善体重指数方面的临床疗效优于单纯应用门冬胰岛素30注射液，且能有效改善糖尿病患者的认知功能。

• 【Abstract】Objective    To investigate the effect of liraglutide combined with insulin aspart 30 injection on type 2 diabetes mellitus and cognitive impairment. Methods    A total of 132 consecutive patients with type 2 diabetes were recruited between September 2014 and January 2016 in Taizhou City Hospital of Zhejiang Province. They were randomly divided into control group and observation group, with 66 cases in each group. The control group was treated with subcutaneous injection of insulin aspart 30. The observation group was treated with liraglutide and insulin aspart 30 injection. Blood glucose, blood lipid, body mass index（BMI） and cognitive function［Mini-Mental State Examination（MMSE）, Montreal Cognitive Assessment（MoCA）, Clinical Memory Scale（CMS）］ were analyzed before and 12 months after treatment. Results    After treatment, blood glucose, lipid and BMI significantly decreased compared to those before treatment; fasting blood glucose, glycosylated hemoglobin and BMI in the observation group were significantly lower than those in the control group［（6.0±1.4）mmol/L vs （6.9±1.1）mmol/L, （6.0±1.8）% vs （7.6±1.6）%， （25.9±6.8）kg/m2 vs （27.9±5.4）kg/m2］（P＜0.05）. After treatment, scores of MMSE, MoCA and CMS significantly increased; the scores in the observation group were significantly higher than those in the control group［（26.9±3.5） vs （25.0±2.8）， （27.1±4.4） vs （25.3±3.3）， （81±12） vs （74±10）］（P＜0.05）. Conclusion    Liraglutide combined with insulin aspart 30 injection has better effects on controlling blood glucose, reducing blood lipid and improving BMI than insulin aspart 30 alone; it can also improve the cognitive function in diabetic patients.